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ABSTRACT
Background Acceptance of the role of the fallopian 
tube in ’ovarian’ carcinogenesis and the detrimental 
sequelae of surgical menopause in premenopausal 
women following risk- reducing salpingo- oophorectomy 
(RRSO) has resulted in risk- reducing early- salpingectomy 
with delayed oophorectomy (RRESDO) being proposed as 
an attractive alternative risk- reducing strategy in women 
who decline/delay oophorectomy. We present the results 
of a qualitative study evaluating the decision- making 
process among BRCA carriers considering prophylactic 
surgeries (RRSO/RRESDO) as part of the multicentre 
PROTECTOR trial (ISRCTN:25173360).
Methods In- depth semistructured 1:1 interviews 
conducted using a predeveloped topic- guide 
(development informed by literature review and expert 
consultation) until informational saturation reached. 
Wording and sequencing of questions were left open 
with probes used to elicit additional information. All 
interviews were audio- recorded, transcribed verbatim, 
transcripts analysed using an inductive theoretical 
framework and data managed using NVIVO- v12.
Results Informational saturation was reached following 
24 interviews. Seven interconnected themes integral 
to surgical decision making were identified: fertility/
menopause/cancer risk reduction/surgical choices/
surgical complications/sequence of ovarian- and- breast 
prophylactic surgeries/support/satisfaction. Women for 
whom maximising ovarian cancer risk reduction was 
relatively more important than early menopause/quality- 
of- life preferred RRSO, whereas those more concerned 
about detrimental impact of menopause chose RRESDO. 
Women managed in specialist familial cancer clinic 
settings compared with non- specialist settings felt 
they received better quality care, improved hormone 
replacement therapy access and were more satisfied.
Conclusion Multiple contextual factors (medical, 
physical, psychological, social) influence timing of risk- 
reducing surgeries. RRESDO offers women delaying/
declining premenopausal oophorectomy, particularly 
those concerned about menopausal effects, a degree 
of ovarian cancer risk reduction while avoiding 
early menopause. Care of high- risk women should 
be centralised to centres with specialist familial 
gynaecological cancer risk management services 
to provide a better- quality, streamlined, holistic 
multidisciplinary approach.
INTRODUCTION
BRCA1/BRCA2 mutation carriers have a ~70% 
lifetime risk of breast cancer (BC) and ~17%–
44% lifetime risk of ovarian cancer (OC).1 RAD51C/
RAD51D/BRIP1/PALB2 are newer moderate pene-
trance OC genes, whose risks were recently vali-
dated (5%–13% lifetime cumulative OC risk) with 
RAD51C/RAD51D/PALB2 also associated with 
increased BC risk (20%–53%).2 3 BC risk manage-
ment options include annual (eg, MRI) breast 
screening;4 chemoprevention (eg, Tamoxifen/Anas-
trazole))5 6 and surgical prevention (risk- reducing 
mastectomy (RRM)).7 Risk- reducing salpingo- 
oophorectomy (RRSO), usually recommended 
from 35 to 40 years, is the most effective surgical 
prevention option for OC- risk reduction, especially 
given the absence of an effective national (or even 
approved) high- risk OC- screening programme. 
However, premenopausal RRSO leads to early 
surgical menopause which has detrimental long- term 
health sequelae (increased risk of coronary heart 
disease, osteoporosis, vasomotor symptoms, sexual 
dysfunction, neurocognitive decline) particularly in 
women unable to use hormone replacement therapy 
(HRT).8–13 Widespread acceptance of a central role 
for the fallopian tube in the development of high- 
grade serous carcinoma (HGSC), the most common 
type of OC has led to early salpingectomy (ES) 
followed by delayed oophorectomy (DO) proposed 
as an attractive alternative two- step OC surgical 
prevention strategy in premenopausal women who 
have completed their family but decline/wish to 
delay RRSO. Epidemiological studies show 70% of 
occult lesions identified in high- risk women under-
going RRSO occur in the tube and that salpingec-
tomy may reduce ovarian cancer risk in low- risk 
women by 42%–65%. Thus, it is anticipated that 
risk- reducing early- salpingectomy with delayed 
oophorectomy (RRESDO) will provide some level 
of risk reduction while conserving ovarian function 
to avoid the negative impact of early menopause.
Three trials in the UK (PROTECTOR), Nether-
lands (TUBA) and US (WISP) are currently offering 
RRESDO within a controlled research setting. 
Absence of prospective data strengthens offering 
RRESDO currently solely within a research setting. 
The precise estimate of OC risk reduction and the 
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long- term health outcomes associated with ES remain unclear. 
Salpingectomy will not prevent OC arising outside the tube. 
Residual fimbrial tissue (most HGSC arise from tubal fimbria) 
may remain implanted on the ovarian surface postsalpingec-
tomy in 9.8% cases14 and represents a possible site of malig-
nant transformation. The natural history of different types of 
serous- tubal intraepithelial carcinoma (STIC), the precursor of 
tubal HGSC and rate- limiting step in OC development remain 
unknown.15 STICs may not be precursors to all OC.16 The long- 
term impact of salpingectomy on sexual function, endocrine 
function and menopause onset is unknown. Concerns remain 
regarding attrition from DO and uncertainties persist around 
cost effectiveness.17
There is a paucity of qualitative data on the decision- making 
process for RRESDO in BRCA carriers.18 Limited data suggest 
that the seriousness of OC, family history (FH), previous BC, 
uncertainty around effect of ES and ease of decision to undergo 
RRSO are barriers to undergoing RRESDO.18 The main facil-
itator is longer preservation of ovarian function.18 RRESDO 
appears acceptable particularly to women concerned about 
sexual dysfunction.19 Barriers to RRSO include early meno-
pause, sexual dysfunction and loss of fertility; facilitators include 
FH, fear of dying, concurrent benign gynaecological issues, inef-
fective screening and physician recommendation.18 20–22
Current medical decision making encourages clinicians to 
respect patients’ preferences and be guided by them for treat-
ment decisions.23 Policy makers and commissioners increas-
ingly use qualitative data to inform guideline development and 
care pathways, as it enables care provision according to user 
insights by gaining a better understanding of, and reasons for 
the choices made. We report on the decision making of high- 
risk UK women undergoing/considering prophylactic surgery in 
the PROTECTOR trial (ISRCTN 25173360). This study aims 
to evaluate the decision- making process among BRCA carriers 
considering prophylactic surgeries. We offer novel insights for 
healthcare professionals providing decision support to BRCA 




Qualitative substudy nested within a multicentre, observa-
tional cohort trial (PROTECTOR: Preventing Ovarian Cancer 
through early Excision of Tubes and late Ovarian Removal, 
ISRCTN:25173360) with three arms: RRESDO; RRSO; no 
surgery.24 Premenopausal women (follicle stimulating hormone 
(FSH) levels<40), >30 years, at increased risk of OC (BRCA1/
BRCA2/RAD51C/RAD51D/BRIP1 carriers or due to a strong 
family history) were recruited to the PROTECTOR trial ( www. 
protector. org. uk) through specialist high- risk familial cancer 
clinics (FCC), genetics, gynaecology/gynaecological oncology 
clinics. Exclusion criteria included being postmenopausal, 
previous bilateral salpingectomy or bilateral oophorectomy, 
pregnancy, future plan of childbearing (surgical arms only), prior 
OC/peritoneal malignancy, <12 months from cancer treatment, 
OC suspicion at baseline. Participants self- selected their chosen 
study arm following informed counselling.
In- depth semistructured one- to- one telephone interviews 
were conducted (by FG) using a predeveloped topic- guide 
(online supplemental material 1). Topic- guide development 
was informed by a literature review and expert consultation. 
Wording and sequencing of questions were left open with probes 
used to elicit more information as appropriate. Questions were 
refined following a pilot interview, and topics covered included: 
background (family structure, support network, occupation, 
hobbies); risk- reducing surgery for OC/BC prevention; health 
values; satisfaction- and- regret. Following informed consent, 
interviewees were recruited based on sociodemographics (age, 
ethnicity, marital status, postcode), parity, BC history, trial arm 
(RRESDO, RRSO, no surgery) and ascertainment location (high- 
risk FCC, gynaecology clinic, gynaecological oncology clinic, 
genetics clinic) to ensure adequate representation across the 
PROTECTOR cohort. Field notes were made, interviews audio- 
recorded and transcribed verbatim. Interviews were conducted 
(before OC prevention surgery) between November 2018 and 
October 2019 until data saturation was reached.
Data analysis
Transcripts were analysed using a grounded- theory approach and 
data managed using NVIVO V.12 software. The analysis aimed to 
directly reflect the views and experiences of participants’ and not 
those predetermined by the researchers. Two researchers (FG, SG) 
independently coded all transcripts, following a three- step process: 
open coding, axial coding and selective coding. Meaningful text 
was labelled starting with a line- by- line analysis (open coding). 
Open codes were categorised, grouping similar codes, refined and 
combined into larger themes (axial coding). Through multiple, iter-
ative discussions, we reflected on potential relationships between 
codes within and across cases and developed an in- depth under-
standing of themes. Coding disagreements were resolved through 
discussion with further transcript review until reaching consensus. 
Transcripts were re- reviewed to ensure themes reflected the data 
and important ideas/views had not been missed/over- represented. 
Selective coding involved integrating and refining themes. Analysis 
was performed in parallel with data collection and finalised once 
theoretical saturation was reached.
RESULTS
Participant characteristics
Twenty- four women were interviewed, with no interview 
refusals. Participant characteristics are summarised in table 1. 
Participants ranged from 34 to 46 years; 22 were Caucasian, 19 
married, 4 nulliparous, 4 had previously BC themselves, 9 had 
undergone RRM, 14 were BRCA1 carriers, 10 BRCA2 carriers, 
11 self- selected RRESDO, 7 RRSO and 6 no surgery. Interviews 
lasted 40–70 (mean=55) min.
Themes
Seven themes pertinent to decision making emerged: fertility; 
menopause; cancer risk reduction: surgical choices; surgical 
complications; sequence of ovarian and breast prophylactic 
surgeries; support with decision making; satisfaction with treat-
ment choices. Table 2 summarises the facilitators and table 3 the 
barriers per- theme and surgical prevention strategy. Figure 1 
maps the decision- making options for premenopausal BRCA 
carriers considering risk- reducing surgery.
Fertility
ID-03 (RRESDO- arm): ‘I just think because I know that 
I’ve completed my family and I don’t want these old tubes 
anymore anyway, I just see it [surgery] as being something 
positive that I can do for myself, to hopefully reduce my 
risk of cancer.’
Fertility was an important consideration for all women. For 18 
women choosing surgery (RRESDO/RRSO), 16 completed child-
bearing and two didn’t want children. Once fertility was not a 
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Surgical complications; satisfaction with 
treatment choices
Positive experience with previous surgery ‘…the trade- off between having two surgeries as opposed to one, that does feel absolutely fine to me, 
and that’s maybe because I've had positive experiences with surgery before.’ (ID-18)
Menopause; satisfaction with treatment 
choices
Flexible timing of delayed oophorectomy ‘I know that there is no guarantee that it prevents ovarian cancer but I see it as being a positive thing 
I can do for myself for now, at my age and I know that if I had any concerns in the future, even before 
I hit menopause, that I could come back and approach you about having my ovaries removed, no- one’s 
telling me, “If you have your tubes out, you have to wait X, we won’t take your ovaries out for this”, 
so I think everyone’s been very open to discussing it and it’s been very focused around how I feel and 
what I want, which is very encouraging.’ (ID-16)
Menopause; satisfaction with treatment 
choices
Avoiding early menopause ‘…what I was most interested in was the fact that it would be two- step because I feel personally, I'm 
too young to be put into menopause, I don’t want to go down that road.’ (ID-03)
Menopause Avoiding the need to take HRT ‘I'd rather just have a little surgery and deal with that for a small amount of time than have to take HRT 
all the time, I'm quite loathed to take drugs really.’ (ID-16)
‘I was worried about the financial implications of having to take something for life.’ (ID-18)
Menopause; satisfaction with treatment 
choices
Concerns HRT may not adequately 
alleviate menopausal symptoms and 
improve QoL
‘…HRT perhaps hasn’t worked out quite as expected or planned or it’s needed a lot of tweaking or 
maybe they haven’t received the level that they’ve needed to and, they haven’t regretted the decision 
because actually they’ve reduced their risk but they’ve actually noticed a significant drop in their 
quality of life that they didn’t actually expect. And, I think it’s really important for people to know that 
that might happen…’ (ID-05)
Cancer risk reduction: surgical choices; 
satisfaction with treatment choices
To reduce anxiety of doing nothing ‘Sometimes you just have to make a decision between two difficult things, where you don’t really want 
to do either of them and doing something is better than doing nothing…’ (ID-16)
Cancer risk reduction: surgical choices Empowerment ‘…I just see it as being something positive that I can do for myself, to hopefully reduce my risk of 
cancer.’ (ID-08)
Cancer risk reduction: surgical choices; 
sequence of ovarian and breast 
prophylactic surgeries; satisfaction with 
treatment choices
Stronger FH of BC than OC ‘There’s more breast than ovary cancer in my family, so I’m probably at higher risk of breast cancer.’ 
(ID-18)
Fertility Childbearing complete ‘I have finished having children so it was an easy decision to make.’ (ID-06)
  RRSO
Surgical complications Single surgery and concerns over future 
health
‘…I think while you’re fit and well, it’s the time to have surgery. The longer you wait, who knows what 
happens when you get older.’ (ID-13)
Surgical complications Straightforward day case surgery ‘…it (salpingo- oophorectomy)sounds like quite a straightforward minor operation and I can go home 
the same day…’ (ID-13)
Cancer risk reduction: surgical choices Wanting maximum OC risk reduction ‘I just want the surgery that will protect me from developing ovarian cancer the most.’ (ID-22)
Menopause Taking HRT acceptable ‘I don’t have any issue taking HRT.’ (ID-20)
Cancer risk reduction: surgical choices Strong family history of OC ‘So many of my relatives have died from ovarian cancer.’ (ID-23)
Fertility Childbearing complete ‘I’m finished having children.’ (ID-20)
Cancer risk reduction: surgical choices No NHS OC screening programme ‘There is no screening on the NHS for ovarian cancer and that means my only other option is to have 
my ovaries out.’ (ID-20)
Cancer risk reduction: surgical choices Inability to self- examine ovaries ‘From the very beginning I felt I was more concerned more about the ovarian cancer risk than the 
breast cancer risk, because I felt like I could effectively examine my own breasts and keep a check on 
that, but I can’t check my ovaries.’ (ID-04)
Cancer risk reduction: surgical choices Poor OC prognosis ‘…it’s very hard to detect ovarian cancer and it has a very poor prognosis, it seemed to make complete 
sense.’ (ID-04)
Support with decision making; cancer risk 
reduction: surgical choices; sequence of 
ovarian and breast prophylactic surgeries
Physician recommendation ‘Counselling from my doctor really helped. She was knowledgeable, supportive and sympathetic of my 
situation. She recommended surgery as I have had all my kids, am 46 and because my aunt died of 
ovarian cancer at 45.’ (ID-04)
  RRM
Cancer risk reduction: surgical choices BC screening anxiety ‘I never went away thinking, “I've got the all clear”, I went away feeling like, “As far as anyone can tell 
I've got the all clear”, and then the anxiety would start to rise again as we headed towards the next 
five month [screening] mark point when I could see it looming in the diary.’ (ID-13)
Fertility Completion of childbearing and breast 
feeding
‘I have finished having kids, so I don’t really need them anymore.’ (ID-02)
Cancer risk reduction: surgical choices; 
sequence of ovarian and breast 
prophylactic surgeries
Strong FH of BC ‘I know that the risk is greater for cancer in the breast as compared to the ovaries because of my family 
history.’ (ID-02)
  Combined breast and ovarian cancer prevention surgeries
Sequence of ovarian and breast 
prophylactic surgeries
Fewer surgeries ‘Just throw everything at it, and let’s just get it all sorted in one.’ (ID-11)
Sequence of ovarian and breast 
prophylactic surgeries
Less anxiety associated with waiting for 
individual surgeries
‘It’s stressful waiting for all the appointment to see different specialists at different times. I would be 
happier if I could have got it all sorted in one go.’ (ID-05)
Sequence of ovarian and breast 
prophylactic surgeries
Fewer hospital appointments ‘The fewer times I need to visit hospital, the better.’ (ID-05)
Sequence of ovarian and breast 
prophylactic surgeries
Less delays waiting for individual 
surgeries
‘I guess there’s no thinking of delaying one or the other, if I've made a decision to reduce my risk, I 
think it would make sense to do them both at the same time.’ (ID-22)
Sequence of ovarian and breast 
prophylactic surgeries; support with 
decision making
Less time off work ‘I’m self employed, so the less time off work, the better.’ (ID-22)
Continued
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barrier, deciding to undergo surgery was less complex and a natural 
next step. Four women had not completed childbearing, wished to 
delay surgery and joined the control arm. Two control arm women 
despite completing childbearing delayed surgery. One was unde-
cided what to choose and the second had strong beliefs against 
removing healthy tissue and any risk- reducing surgery.
Two women opted to conceive through in vitro fertilisa-
tion (IVF) and preimplantation genetic diagnosis (PGD). Both 
acknowledged PGD/IVF was physically and mentally stressful 
with multiple hospital visits and additional procedures but 
considered it an acceptable tradeoff to prevent their children 
being BRCA carriers and facing similar difficult decisions. One 
participant felt she may have not proceeded with a natural 




Sequence of ovarian and breast 
prophylactic surgeries
Single postoperative recovery ‘I would prefer to recover just once from surgery.’ (ID-18)
Sequence of ovarian and breast 
prophylactic surgeries; fertility
Childbearing complete ‘Because I’m done having kids, I just want it all out.’ (ID-23)
BC, breast cancer; HRT, hormone replacement therapy; OC, ovarian cancer; QoL, quality of life; RRESDO, risk- reducing early salpingectomy with delayed oophorectomy; RRM, risk- reducing 
mastectomy; RRSO, risk- reducing- salpingo- oophorectomy.
Table 2 Continued
Table 3 Thematised barriers to uptake of risk reducing surgeries
Themes Barriers Quotes
  RRESDO
Menopause; satisfaction with treatment 
choices
Approaching the age of natural menopause ‘I think my age, I think it’s the fact that they [surgeries] might have ended up being within two or 
three years, it just didn’t make that much sense to me…’ (ID-20)
Cancer risk reduction; sequence of 
ovarian and breast prophylactic surgeries
Strong family history of OC ‘I am more concerned about protecting myself from ovarian cancer because I have more relatives with 
ovarian cancer than breast cancer and so I just want the lot [tubes and ovaries] out.’ (ID-23)
Cancer risk reduction: surgical choices Two staged surgery ‘To be honest, I think if you’re going to go and have it done, have it done in one. Why would I want, in 
another 10 years, to go and have surgery again?’ (ID-23)
Surgical complications Concerns over future poor health ‘I don’t know what my health would be like in 10 years’ time, I might not be up for surgery. I just 
think get it done, get it over and done with now.’ (ID-20)
Cancer risk reduction: surgical choices; 
satisfaction with treatment choices
More effective surgery to reduce OC risk ‘…I just want to eliminate as much [risk] as possible…’ (ID-20)
Fertility Childbearing not complete ‘I have not finished having children…’ (ID-01)
  RRSO
Fertility Childbearing not complete ‘I have not finished having children…’ (ID-14)
Fertility Not wanting to remove healthy tissue ‘It’s also quite difficult to decide to go through an operation when there’s nothing wrong, so obviously 
it’s preventative but part of you is like “I'm perfectly healthy, why would I do this?”’(ID-01)
Menopause; satisfaction with treatment 
choices
Early menopause ‘I was very off put by that [oophorectomy] because I feel I'm too young to be put into the menopause 
and I'm aware, probably through training as a nurse, the symptoms associated with that, the 
increased risk of, I would be decreasing my risk obviously of ovarian cancer but then have an 
increased risk of osteoporosis and all the other things, it was trying to weigh up the best option and I 
didn’t feel that that’s something I wanted to think of at this moment in time.’ (ID-01)
  RRM
Cancer risk reduction: surgical choices Loss of femininity and self esteem ‘My breasts are my womanhood and loosing them I think would really effect my self esteem and not 
in a good way.’ (ID-15)
Fertility Childbearing and breastfeeding not 
complete
‘I still need my breasts to breastfeed. I’ve not finished having kids.’ (ID-03)
Surgical complications; satisfaction with 
treatment choices
Major operation with long recovery ‘…it’s a major operation, psychologically and physically with long recovery.’ (ID-03)
Cancer risk reduction: surgical choices Effective BC screening programme ‘There is such an effective screening programme, I wouldn’t want surgery unless there was something 
picked up on a scan.’ (ID-04)
Cancer risk reduction: surgical choices Good prognosis from early screen detected 
BC
‘…breast cancer is quite treatable and has often a good prognosis.’ (ID-04)
  Combined ovarian and breast cancer prevention surgeries
Sequence of ovarian and breast 
prophylactic surgeries; satisfaction with 
treatment choices
Increased duration of postoperative 
recovery
‘I would be worried that recovery from such a big operation would be really long.’ (ID-23)
Sequence of ovarian and breast 
prophylactic surgeries; satisfaction with 
treatment choices
Concerns over increased number of 
complications
‘…primarily it will be around the additional risk of complications and side effects from the various 
elements of the two different surgeries…’ (ID-23)
Sequence of ovarian and breast 
prophylactic surgeries; satisfaction with 
treatment choices
Psychological distress ‘I don’t think I would cope well with going into menopause the same time as losing my breasts and 
all the implications that would have on me feeling like a woman.’ (ID-22)
BC, breast cancer; HRT, hormone replacement therapy; OC, ovarian cancer; QoL, quality of life; RRESDO, risk- reducing early salpingectomy with delayed oophorectomy; RRSO, risk- reducing 
salpingo- oophorectomy.
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Menopause
ID-06 (RRESDO- arm): ‘I wasn’t happy with the impact 
of going in to menopause straight away and although you 
obviously have HRT options which might be offered if you 
go to a good gynaecologist, I just, I wasn’t convinced that 
HRT brings you back up to an even keel or level, the way 
that I’m feeling right now which is basically very balanced.’
Interviewees who chose RRESDO (n=11) did so because of 
concerns about detrimental consequences of early menopause 
following oophorectomy, particularly low mood, sexual dysfunc-
tion and poorer QoL. All RRESDO interviewees found the uncer-
tainty regarding long- term health implications (eg, possibility of 
earlier menopause following ES) an acceptable risk. Interviewees 
rationalised RRESDO as a preferential strategy to delay early 
menopause and its long- term consequences while benefiting 
from some OC risk reduction. Two women would have delayed 
risk- reducing surgery until they were near/at natural menopause 
if RRESDO was unavailable, whereas another would have under-
gone RRSO instead. Two RRESDO women found avoiding need 
for HRT and repeat prescription costs more appealing. RRESDO 
interviewees wanted to be in control of choosing the timing of 
DO (with their clinician) and felt a fixed timing for DO was a 
barrier to RRESDO uptake. Menopause was a lesser concern to 
older premenopausal women (nearer the age of natural meno-
pause) self- selecting RRSO because RRESDO would only delay 
menopause by a few years and require an additional operation.
RRSO women managed outside specialist high- risk clinics 
reported receiving conflicting advice on HRT safety, lack of 
information on HRT efficacy for symptom relief and struggling 
with HRT access. A number of gynaecologists/gynaecological 
oncologists do not routinely counsel women about health conse-
quences of early menopause, lack awareness of HRT safety and 
do not offer HRT to BRCA carriers undergoing premenopausal 
RRSO (particularly those near natural menopause age). Women 
attending BRCA support forums felt unsupported without 
follow- up after surgery and reported persistent menopausal 
symptoms detrimentally affecting QoL despite HRT. Women 
managed within a high- risk FCC reported being more reas-
sured with their planned follow- up and access to a menopause 
specialist post- RRSO.
Cancer risk reduction: surgical choices
Ovarian-cancer risk-reducing surgery
ID-08 (RRESDO- arm): ‘It’s [RRESDO] acceptable because 
it’s my decision making as well, it’s not at the fault of any 
health professional, no- one is making me do it this way, it’s 
my decision and I'm aware of that.’
Women who prioritised avoiding menopause and preserving 
QoL selected RRESDO. While, women concerned about the 
precision of risk reduction and who prioritised maximising OC 
risk reduction, selected RRSO. Women with a strong FH of OC 
selected RRSO, and with strong FH of BC preferred RRESDO.
RRESDO interviewees felt comfortable and empowered with 
the tradeoff between an uncertain degree of OC risk reduction 
and avoidance of early menopause. They rationalised they were 
doing ‘…something to reduce risk as opposed to nothing…’ while 
avoiding early menopause and preserving their QoL.
A few interviewees reported being counselled/reading they 
were at increased endometrial cancer risk and were offered/
requested a concomitant hysterectomy.
Breast-cancer risk-reducing surgery
ID-01 (No- surgery- arm): ‘…it’s also quite difficult to decide 
to go through a major operation when there’s nothing 
wrong, so obviously it’s preventative but part of you is like 
“I'm perfectly healthy, why would I do this?”, and there’s 
something quite emotional about the idea of having your 
Figure 1 Decision making aid for premenopausal BRCA carriers considering risk reducing surgery. BC, breast cancer; HRT, hormone replacement therapy; 
OC, ovarian cancer; RRESDO, risk reducing early salpingectomy with delayed oophorectomy; RRM, risk reducing mastectomy; RRSO, risk reducing salpingo- 
oophorectomy.
 on M








enet: first published as 10.1136/jm





7Gaba F, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2020-107501
Cancer genetics
breast removed as well, whereas the ovaries aren’t seen, 
it’s about appearance as well and just having implants and 
things like that.’
Interviewees considered RRM decision making much harder 
compared with RRSO/RRESDO. Women were conflicted with 
wanting to optimise BC prevention while preserving breasts for 
femininity and self- esteem. They preferred delaying RRM until 
finishing childbearing and breastfeeding.
ID-13 (RRSO- arm): ‘I never went away thinking, “I've got the all 
clear”, I went away feeling like, “As far as anyone can tell I've got 
the all clear”, and then the anxiety would start to rise again as we 
headed towards the next five month mark point when I could see it 
looming in the diary.’
Some women reported anxiety/stress with breast s
Nine women underwent RRM and five struggled with decision 
making on reconstruction with flaps or implants; and consider-
ation of nipple- sparing versus non- nipple- sparing surgeries. Two 
highlighted lack of healthcare professional support for women 
opting against reconstruction. One interviewee regretted her 
decision of flap reconstruction due to resultant cosmetic appear-
ance and chronic pain but did not regret RRM.
All BC- affected interviewees selected OC- prevention surgery 
purely for preventing OC. They felt alternative treatments were 
available to improve BC survival. Women selecting RRESDO did 
not consider the potential loss of improved BC- survival from 
oophorectomy a barrier.
Surgical complications
ID-18 (RRESDO- arm): ‘…the trade- off between having two 
surgeries as opposed to one, that does feel absolutely fine to 
me, and that’s maybe because I've had positive experiences 
with surgery before.’
Women with previous positive surgical experiences (good 
relationship with surgeon, postoperative care, no complica-
tions) and/or good health found two- staged RRESDO accept-
able, without concerns for increased surgical complications or 
hospital appointments. Inspection of pelvis/abdomen for OC at 
RRES was reassuring for one patient. One RRSO interviewee 
highlighted concerns of two surgeries as future health may dete-
riorate with age and increase risks of surgical complications.
Sequence of ovarian and breast prophylactic surgeries
Sequential surgery
ID-16 (RRESDO- arm): ‘Because I’ve never had an operation, 
I thought it would be better to have a minor operation first, 
just to kind of prepare me rather than going straight into 
major surgery, that was one reason but the other was the 
ovarian cancer prevention felt more pressing because I'm 
on the breast screening programme and it didn’t feel quite 
so urgent.’
Interviewees reported preferring OC prevention surgery 
before RRM because of lack of an OC screening programme; 
poorer prognosis of OC; being a laparoscopic procedure with 
quick recovery; inability to self- examine ovaries. Women with a 
stronger FH of OC preferred RRSO first and those with a FH of 
BC chose undergoing RRM first. Sequence was also dependent 
on surgical referral and appointment times with some experi-
encing shorter waiting times for seeing a breast surgeon than a 
gynaecologist/gynaecological oncologist.
Combined ovarian and breast prophylactic surgery
ID-11 (RRESDO- arm): ‘Just throw everything at it, and 
let’s just get it all sorted in one.’
Fifteen women would have preferred a single combined risk- 
reducing procedure involving RRM±reconstruction along with 
OC preventative surgery. Reasons included fewer surgeries, less 
anxiety, less waiting, fewer appointments, less time off work 
and single surgical recovery. However, nine women expressed 
concerns over possible increased recovery time and increased 
psychological distress from early menopause impacted by RRM 
associated body image issues.
Support with decision making
Clinical support
ID-05 (RRESDO- arm): ‘…my experience of [gynaecology] 
appointments is that people just present things to you, and 
very quickly you have to make a decision, and there isn’t a 
way to just, some of the decisions take a lot of discussion, 
and coming back to it, and rethinking, and I just feel that 
there isn’t that space for it…’
Interviewees expressed preference for multiple appointments 
with gynaecologists/gynaecological oncologists for discussing 
risk- reducing surgery. Decision making was a complex/dynamic 
process, with one visit being inadequate to absorb/assimilate 
complex information, and make an informed decision. Inter-
viewees felt more supported with RRM decision making, given 
access to a psychologist and multiple breast surgical appoint-
ments before RRM. Interviewees wished to be routinely offered 
an ‘optional’ (not compulsory) consultation with a psychologist 
prior to OC preventative surgery.
Interviewees who had done personal research (reading litera-
ture, speaking to BRCA carriers, online support groups (OSGs)) 
felt their decision was validated following counselling from 
healthcare professionals. Counselling received aided decision 
making of women who had not done any personal research. 
Counselling lacked information on communicating genetic test 
results to children and complex decisions carriers faced.
Patient support groups
ID-05 (RRESDO- arm): ‘I know there are [online] forums, 
but a lot of it, there’s a lot of fearful ideas there, and my 
cousin was saying that she just had to stop going on those 
forums.’
Continuous availability/access and anonymity were advan-
tages of online BRCA support groups/forums reported by 
our cohort. However, interviewees also highlighted nega-
tive personal experiences (and anxiety) given poor surgical 
outcomes/negative experiences discussed at these outlets which 
were not balanced with positive outcomes. Interviewees used 
online forums for an ad- hoc- specific query rather than for 
regular support. Clinician- led educational days with experts’ 
talks about management options, opportunities to ask ques-
tions, share experiences and meet other BRCA carriers appeared 
preferable.
Lifestyle support
ID-22 (RRSO- arm): ‘When I realised that I’d have to go 
through with a number of operations to help reduce the risk, 
I made sure that I was in the best possible health beforehand 
to deal with those and I was really glad that I did.’
RRESDO/RRSO women were eating healthier, losing weight 
and exercising regularly to minimise postoperative complications 
and shorten recovery time. Even no- surgery interviewees made 
healthier choices (smoking cessation, reduced alcohol, exercise, 
diet) to increase their conception chances.
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Satisfaction with treatment choices
ID-16 (RRESDO- arm): ‘I'm at peace over the situation, and 
it’s not something that has caused me anxiety, although I 
don’t really like procedures and hospitals as I've said, but I 
feel that it’s something that I can manage.’
Interviewees felt it difficult to state outright satisfaction 
with their decision to have/not have preventative surgery but 
rationalised their decision making. Women delaying surgery 
were concerned about developing cancer. Women undergoing 
surgery were also concerned about developing cancer along with 
surgical complications, impact on QoL and psychological health. 
However surgery reduced OC/BC anxiety.
ID-18 (RRESDO- arm): ‘I’d done quite a bit of research myself. I 
found all of the people that I’ve met within the team have been 
fantastic and haven’t just treated me like Patient X who doesn’t 
know anything at all.’
Interviewees managed within high- risk multidisciplinary FCC 
appeared more satisfied than those managed in genetics/gynae-
cology/gynaecological oncology clinics. Reasons included a more 
personalised approach, information tailored to the individu-
al’s pre- existing knowledge base, same- day consultations with 
multiple specialists and continuity of care. The combination 
of specialists supporting FCCs varied but included: geneticists, 
gynaecologists, breast surgeons, menopause specialists, fertility 
specialists, psychologists. All seven women previously under the 
care of non- specialist clinics reported higher satisfaction levels 
when subsequently managed in the FCC setting.
ID-13 (RRSO- arm): ‘…it does take time, like relieve yourself of 
that sense of pressure of having to come to a decision…’
Interviewees would advise fellow BRCA carriers to avoid 
time- pressure with surgical decision making, talk to other BRCA 
carriers, do personal research, ask for second opinions if not 
satisfied.
No- surgery interviewees would regret their decision to delay/
avoid surgery if they developed OC. Women undergoing surgery 
would regret it if a life- changing surgical complication occurred.
DISCUSSION
We identified seven interconnected themes integral to surgical 
prevention decision making in BRCA carriers. To the best of our 
knowledge, this is the first qualitative study that has mapped all 
aspects of the decision- making process of BRCA carriers under-
going/considering all ovarian (RRESDO/RRSO)/breast (RRM)/
combined risk- reducing surgical options (figure 1). Women 
for whom maximising OC risk reduction was relatively more 
important than early menopause/QoL preferred RRSO, whereas 
those more concerned about impact of menopause chose 
RRESDO.
While some facilitators/barriers we describe for RRESDO 
are similar to those reported earlier, we found some differences 
too.18 19 25 Unlike a Dutch study reporting a personal history 
of BC as a barrier, we report that BC- affected BRCA carriers 
found RRESDO acceptable despite potential for improved BC 
survival afforded by premenopausal oophorectomy. BC- affected 
and unaffected BRCA carriers selecting RRESDO were equally 
concerned about avoiding early menopause/maintaining QoL. 
This apparent difference in RRESDO acceptability among UK 
and Dutch women may be attributed to differences in counsel-
ling, risk- management options available, population differences, 
evolving scientific evidence base, its interpretation by clinicians 
and patients and changing practices. Oophorectomy may not 
reduce primary/contralateral BC risk26–29 and effective adjunct 
treatments to improve BC outcomes are available including 
contralateral mastectomy, GnRH analogues, selective estrogen 
receptor modulators etc.
Approaching the age of natural menopause and concerns over 
future poor health were new barriers to RRESDO we elicited. 
Previously unreported RRESDO facilitators identified include 
avoiding the need for HRT and significant concerns about not 
adequately alleviating menopausal symptoms or improving QoL. 
This highlights women’s unease and apprehension related to 
effects of menopause.30 Premenopausal women concerned about 
sexual dysfunction are more likely to opt for RRESDO.19 Despite 
HRT, symptom levels following premenopausal oophorectomy, 
particularly for sexual dysfunction, remain above those retaining 
their ovaries.31 As part of RRSO decision making all premeno-
pausal women should be involved in formulating an individual-
ised presurgical HRT plan and fully counselled on menopausal 
issues along with the benefits and limitations of HRT.
Other RRESDO facilitators we identified include positive 
experience with previous surgery, reducing the anxiety of doing 
nothing and flexible timing of DO. The Dutch- TUBA,32 and 
US- PSDO (Prophylactic Salpingectomy with Delayed Oopho-
rectomy)33 studies undertake DO well before onset of meno-
pause (without the option to delay until natural menopause). 
This could have been a barrier for UK women. However, in the 
UK PROTECTOR, and US WISP (Women Choosing Surgical 
Prevention)6 trials, women can choose when to undergo DO but 
are encouraged to do this by natural menopause. The facilitator 
and barriers to RRSO/RRM elicited in our cohort are similar to 
those reported earlier.22 33–37
We too found undergoing preventative surgery reduced 
anxiety.18 34 35 Although RRM decision making was more 
complex than OC preventative surgery, women felt more 
supported in their decision to undergo RRM (than OC preven-
tion) due to psychology input and multiple breast surgical 
appointments. This reflects the well- established tertiary care BC 
risk- management pathways in the UK.38 We found disparities in 
OC risk management care across the UK. Women managed in 
high- risk FCC settings were more satisfied with their care and 
received better support and HRT access. The lower satisfac-
tion in women managed in non- specialist clinics was linked to 
non- streamlined clinical pathways, need for multiple referrals, 
delays in seeing different specialists, lack of continuity of care 
and difficulties in assimilating large volumes of information in 
a single appointment. Others too have reported low satisfac-
tion with poorly developed care pathways.36 39 Of particular 
concern was poor HRT counselling and management, also 
reported previously.20 High- risk women need to be supported 
by a multidisciplinary team comprising geneticists, gynaecolo-
gists/gynae- oncologists with a special interest, breast oncologists, 
oncoplastic surgeons, menopause specialists, fertility specialists, 
psychologists and specialist nurses. Our findings support central-
ising care of high- risk women to centres which have specialist 
high- risk multidisciplinary FCC services and the need to develop 
more such services/centres with well- defined care pathways.
Our data suggest that women engage concurrently in both OC 
and BC prevention decision making in contrast to some studies 
suggesting that women prioritise decisions and make them one at 
a time.36 40 41 We identified a demand for combined OC- and- BC 
prevention surgery. However, only few centres currently offer 
this, the psychological/QoL effects following combined BC/
OC prophylactic surgery are unknown and not all women 
may be suitable candidates. Combined surgery offers logistical 
practicality for busy working women with dependent families 
by limiting the hospital appointments/surgeries/postoperative 
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recoveries and has high satisfaction.40 Initial data suggest that a 
combined approach has lower costs than separate procedures40 
but formal cost- utility analysis including sensitivity analysis is 
needed. Additionally, RRESDO may be more acceptable than 
RRSO for combined surgery given the potential for menopausal 
symptoms while recovering from effects of mastectomy.
Benefits of OSGs42–44 include fluid informational exchange, 
continuous availability, greater access/anonymity and were also 
reported by our cohort. Our cohort reported increasing anxiety 
with OSGs and a preference for educational support groups 
(ESGs). ESGs involve face- to- face group activities where partici-
pants and clinicians share their experiences and expertise, along 
with a patient representative acting as the group spokesperson. 
Women found the opportunity to ask experts questions and 
meet other BRCA carriers face- to- face more helpful than OSGs. 
Although small randomised controlled trials (RCTs) have shown 
lower anxiety/depression with OSGs (compared with clinical 
care) in BC women,45 these results may not be generalisable to 
BRCA previvors unaffected by cancer. Large, well- designed RCTs 
comparing OSG with ESG are needed. Another gap we identi-
fied was support women needed to communicate to their chil-
dren genetic test results and the complex decisions they faced. 
Options to address this may include customised information 
sheets/decision aids, offering family counselling. While family 
counselling is established for informing children of a parent’s 
cancer diagnosis,46 outcome data and pathways for this in a 
previvor setting are needed.
Strengths of our study include a robust methodological 
approach using semistructured in- depth interviews until reaching 
data saturation, independent data analysis by two researchers 
and a comprehensive three- step coding process. Our sample was 
broad- based and included women who declined surgery, had a 
personal history of BC, parous/nulliparous, ascertainment from 
a variety of outpatient settings and different UK geographical 
locations. Limitations include that only two interviewees were 
non- Caucasian and there may be cultural nuances affecting the 
decision- making process in ethnic minorities. Also, women who 
had undergone RRM were interviewed retrospectively, ensuing 
a risk of recall bias.
Medical, physical, psychological and social contextual factors 
influence the timing of risk- reducing surgeries. RRESDO offers 
premenopausal women who would otherwise delay/decline 
premenopausal oophorectomy a degree of OC risk reduction 
while avoiding the detrimental sequelae of early menopause. 
The addition of RRESDO as a two- stage surgical alternative 
to RRSO, adds an additional dimension to an already complex 
decision- making process, so it is possible it may increase length 
of time for women to come to a decision regarding OC preven-
tion surgery. Women who prioritise maximising OC risk reduc-
tion favour selecting RRSO, whereas those who prioritised 
maintaining QoL and avoiding menopause preferred RRESDO. 
Our cohort of women expressed a clear interest in combined 
breast- and- ovarian prophylactic surgeries. Women managed in 
specialist FCC settings compared with non- specialist settings 
received better quality care, better HRT access and were more 
satisfied. There is need for centralising the care of women at 
risk of familial gynaecological cancers to centres within special-
ist- FCC services which are able to provide a more streamlined, 
holistic multidisciplinary approach.
Author affiliations
1Wolfson Institute of Preventive Medicine, Barts CRUK Centre, Queen Mary University 
of London—Charterhouse Square Campus, London, UK
2Gynaecological Oncology, Barts Health NHS Trust, London, UK
3Wolfson Institute of Preventive Medicine, Queen Mary University of London, 
London, UK
4Department of Public Health, Environments and Society, Faculty of Public Health 
and Policy, London School of Hygiene & Tropical Medicine, London, UK
5Centre for Experimental Cancer Medicine, Barts CRUK Cancer Centre, Queen Mary 
University of London, London, UK
6Health Services Research and Policy, London School of Hygiene and Tropical 
Medicine, London, UK
7Department of Gynaecology, University College London Hospitals NHS Foundation 
Trust, London, UK
8Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK
9South West Thames Regional Genetics Service, South West Thames Regional Genetic 
Services, London, UK
10Department of Pathology, Barts Health NHS Trust, London, UK
11Centre for Genomic Medicine, University of Manchester, Manchester, UK
12MRC Clinical Trials Unit, University College London, London, UK
13Department of Gynaecological Oncology, Barts Health NHS Trust, London, UK
Twitter Ranjit Manchanda @ProfManchanda
Acknowledgements We are grateful to all women took part in the interviews. We 
are grateful to the central trials coordinating team at the Centre for Experimental 
Cancer Medicine at QMUL, led by Kelly Mousa. We are grateful to the independent 
members of the trial steering committee (chaired by Mr Tim Mould) and the data 
monitoring committee (chaired by Professor Richard Edmondson) and central 
pathology committee (Professor Naveena Singh (chair), Professor W Glenn 
McCluggage, Dr Raji Ganesan, Dr Gareth Bryson, Dr Gareth Rowlands, Dr Rupali 
Arora). We acknowledge support provided by a number of charities and stakeholders 
including BRCA Umbrella (Caroline Presho), The Eve Appeal, Ovacome, Target Ovarian 
Cancer and Ovarian Cancer Action. GDE is supported through the NIHR Manchester 
Biomedical Research Centre (IS- BRC-1215–20007). We are grateful to all our 
collaborators of the PROTECTOR study: Dr Munaza Ahmed (North East Thames 
Cancer Genetics Service, Great Ormond Street Hospital NHS Foundation Trust), Dr 
Aarti Sharma (Cardiff and Vale UHB), Dr Gautam Mehra (Guy’s and St Thomas’ NHS 
Foundation Trust), Dr Adam Rosenthal (University College London Hospitals NHS 
Foundation Trust), Dr Ian Harley (Belfast Health & Social Care Trust), Dr Michelle 
Mackintosh & Prof Emma Crosbie (Manchester University NHS Foundation Trust), 
Professor Sadaf Ghaem- Maghami (Imperial College Healthcare NHS Trust), Professor 
Omer Devaja (Maidstone and Tunbridge Wells NHS Trust), Professor Sudha Sundar 
and Mr Janos Balega (Sandwell and West Birmingham Hospitals NHS Trust), Dr Tim 
Duncan (Norfolk and Norwich University Hospitals NHS Foundation Trust), Dr Iain 
Cameron (Gateshead Health NHS Foundation Trust), Dr Claire Newton (University 
Hospitals Bristol NHS Foundation Trust), Dr Sonali Kaushik (Brighton and Sussex 
University Hospitals NHS Trust), Dr Angela Brady (London North West Healthcare 
NHS Trust), Dr Supratik Chattopadhyay (University Hospitals of Leicester NHS Trust), 
Dr Natalia Povolotskaya (Portsmouth Hospitals NHS Trust), Dr Rema Iyer (East Kent 
Hospitals University NHS Trust), Dr Lucy Side (University Hospital Southampton NHS 
Foundation Trust), Dr Katie Snape (St George’s University Hospitals NHS Foundation 
Trust), Dr Anil Tailor (Royal Surrey County Hospital Foundation Trust), Dr Manon 
van Seters (Worcestershire Acute Hospital Trust), Dr Katherine Edey (Royal Devon 
& Exeter NHS Foundation Trust), Dr Sian Taylor (Liverpool Women’s Hospital NHS 
Foundation Trust), Dr Suma Kodiathodi (North Tees and Hartlepool NHS Foundation 
Trust), Dr Partha Sengupta (County Durham and Darlington NHS Foundation Trust), 
Dr Scott Fegan (NHS Lothian), Dr Karin Williamson (Nottingham University Hospitals 
NHS Trust), Dr Andrew Phillips (University Hospitals of Derby and Burton NHS 
Foundation Trust), Dr Mark Willett (East Lancashire Hospitals NHS Trust), Dr Tony 
Chalhoub (The Newcastle upon Tyne Hospitals NHS Foundation Trust), Dr Sanjay 
Rao (South Tees Hospitals NHS Foundation Trust), Dr Nicholas Matthews (South 
Tyneside and Sunderland NHS Foundation Trust), Dr Beena Abdul (Northampton 
General Hospitals NHS Trust), Dr Ibraheem Hamoodi (Northumbria Healthcare NHS 
Foundation Trust), Dr Claire Park (Royal United Hospitals Bath NHS Foundation 
Trust), Dr Jane Borley (Royal Cornwall Hospitals NHS Trust), Dr Richard Hutson (Leeds 
Teaching Hospitals NHS Trust), Dr Kerryn Lutchman- Singh (Swansea Bay University 
Health Board), Dr Richard Peevor (Betsi Cadwaladr University Health Board), Dr 
Mahalakshmi Gurumurthy (NHS Grampian), Dr Kalpana Ragupathy (NHS Tayside).
Collaborators The PROTECTOR team: Raji Ganesan; Gareth Bryson; Gareth 
Rowlands; Rupali Arora; Munaza Ahmed; Aarti Sharma; Gautam Mehra; Adam 
Rosenthal; Michelle Mackintosh; Sadaf Ghaem- Maghami; Omer Devaja; Sudha 
Sundar; Janos Balega; Tim Duncan; Claire Newton; Sonali Kaushik; Angela Brady; 
Supratik Chattopadhyay; Natalia Povolotskaya; Iain Cameron; Rema Iyer; Lucy 
Side; Katie Snape; Anil Tailor; Kavitha Thumuluru Madhuri; Katherine Edey; Sian 
Taylor; Manon van Seters; Suma Kodiathodi; Partha Sengupta; Scott Fegan; Karin 
Williamson; Andrew Phillips; Mark Willett; Tony Chalhoub; Sanjay Rao; Nicholas 
Matthews; Beena Abdul; Claire Park; Jane Borley; Ibraheem Hamoodi; Richard 
Hutson; Kerryn Lutchman- Singh; Richard Peevor; Mahalakshmi Gurumurthy; Kalpana 
Ragupathy; Emma Crosbie.
 on M








enet: first published as 10.1136/jm





10 Gaba F, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2020-107501
Cancer genetics
Contributors Conception of qualitative study: FG, RM. Qualitative design and 
development: FG, RM, DM. Qualitative data collection: FG. Trial management: FG, SR, 
CT, NS, GDE, UM, RL, ES, WGM, HH, RM. Data analysis: FG, SG, RM, DM. Preparation 
of tables and figures: FG, OE. Initial draft of manuscript: FG, RM, DM. Manuscript 
writing and approval: all authors.
Funding The study is supported by researchers at the Wolfson Institute of 
Preventive Medicine, Queen Mary University of London (C16420/A18066). This work 
was supported and funded by Barts and The London Charity and Rosetrees Trust.
Disclaimer The funding bodies had no role in the study design, data collection, 
analysis, interpretation or writing of the report or decision to submit for publication. 
The research team was independent of funders.
Competing interests RM declares research funding from Cancer Research 
UK and The Eve Appeal outside this work, an honorarium for grant review from 
Israel National Institute for Health Policy Research and honorarium for advisory 
board membership from Astrazeneca/MSD. RM is supported by an NHS Innovation 
Accelerator (NIA) Fellowship for population testing.
Patient consent for publication Not required.
Ethics approval The PROTECTOR Study received full ethics approval from London- 
Bloomsbury Research Ethics Committee (18/LO/0555). The study was registered with 
the International Standard Randomised Controlled Trial Number Register- ISRCTN 
25173360 (https:// doi. org/ 10. 1186/ ISRCTN25173360).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request.
Supplemental material This content has been supplied by the author(s). It 
has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have 
been peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Helen Hanson http:// orcid. org/ 0000- 0002- 3303- 8713
Ranjit Manchanda http:// orcid. org/ 0000- 0003- 3381- 5057
REFERENCES
 1 Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K- A, Mooij TM, Roos- Blom M- J, 
Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, 
Easton DF, Antoniou AC, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, 
Ong K- R, Izatt L, Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues 
C, Lasset C, Stoppa- Lyonnet D, Fricker J- P, Faivre L, Berthet P, Hooning MJ, van der 
Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, 
Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard 
J, Friedlander ML, McLachlan S- A, Machackova E, Foretova L, Tan YY, Singer CF, Olah 
E, Gerdes A- M, Arver B, Olsson H, BRCA1 and BRCA2 Cohort Consortium. Risks of 
breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation 
carriers. JAMA 2017;317:2402–16.
 2 Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, Dunning AM, Redman J, 
Scarth J, Plaskocinska I, Luccarini C, Shah M, Pooley K, Dorling L, Lee A, Adank MA, 
Adlard J, Aittomäki K, Andrulis IL, Ang P, Barwell J, Bernstein JL, Bobolis K, Borg Åke, 
Blomqvist C, Claes KBM, Concannon P, Cuggia A, Culver JO, Damiola F, de Pauw A, 
Diez O, Dolinsky JS, Domchek SM, Engel C, Evans DG, Fostira F, Garber J, Golmard L, 
Goode EL, Gruber SB, Hahnen E, Hake C, Heikkinen T, Hurley JE, Janavicius R, Kleibl 
Z, Kleiblova P, Konstantopoulou I, Kvist A, Laduca H, Lee ASG, Lesueur F, Maher ER, 
Mannermaa A, Manoukian S, McFarland R, McKinnon W, Meindl A, Metcalfe K, Mohd 
Taib NA, Moilanen J, Nathanson KL, Neuhausen S, Ng PS, Nguyen- Dumont T, Nielsen 
SM, Obermair F, Offit K, Olopade OI, Ottini L, Penkert J, Pylkäs K, Radice P, Ramus SJ, 
Rudaitis V, Side L, Silva- Smith R, Silvestri V, Skytte A- B, Slavin T, Soukupova J, Tondini C, 
Trainer AH, Unzeitig G, Usha L, van Overeem Hansen T, Whitworth J, Wood M, Yip CH, 
Yoon S- Y, Yussuf A, Zogopoulos G, Goldgar D, Hopper JL, Chenevix- Trench G, Pharoah 
P, George SHL, Balmaña J, Houdayer C, James P, El- Haffaf Z, Ehrencrona H, Janatova 
M, Peterlongo P, Nevanlinna H, Schmutzler R, Teo S- H, Robson M, Pal T, Couch F, 
Weitzel JN, Elliott A, Southey M, Winqvist R, Easton DF, Foulkes WD, Antoniou AC, 
Tischkowitz M. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An 
International Study of 524 Families. J Clin Oncol 2020;38:Jco1901907:674–85.
 3 Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher 
D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, 
Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomäki K, 
Pelttari LM, Ehrencrona H, Borg Åke, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, 
Dennis J, Bowtell DD, Traficante N, Diez O, Balmaña J, Gruber SB, Chenevix- Trench G, 
Investigators kConFab, Jensen A, Kjær SK, Høgdall E, Castéra L, Garber J, Janavicius 
R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, 
Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler 
RK, Pharoah PDP, Antoniou AC. Ovarian and breast cancer risks associated with 
pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst 2020;112:1242–50.
 4 NICE, Familial Breast Cancer. Classification and care of people at of familial breast 
cancer and management of breast cancer and related risks in people with a family 
history of breast cancer (CG164). London, UK: National Institute for Health and Care 
Excellence, 2013.
 5 Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche 
N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, IBIS- II investigators. 
Anastrozole for prevention of breast cancer in high- risk postmenopausal women 
(IBIS- II): an international, double- blind, randomised placebo- controlled trial. Lancet 
2014;383:1041–8.
 6 Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, International 
Breast Cancer Intervention Study I Investigators. Long- term results of tamoxifen 
prophylaxis for breast cancer--96- month follow- up of the randomized IBIS- I trial. J 
Natl Cancer Inst 2007;99:272–82.
 7 Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, Evans GR, 
Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL. Bilateral prophylactic 
mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the 
PROSE Study Group. J Clin Oncol 2004;22:1055–62.
 8 Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, 
Manson JE. Long- term mortality associated with oophorectomy compared with 
ovarian conservation in the nurses’ health study. Obstet Gynecol 2013;121:709–16.
 9 Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BHR, Oosterwijk JC, Slart 
RHJA, van der Veer E, de Bock GH, Mourits MJE. Bone mineral density and fractures 
after risk- reducing salpingo- oophorectomy in women at increased risk for breast and 
ovarian cancer. Eur J Cancer 2015;51:400–8.
 10 Fakkert IE, van der Veer E, Abma EM, Lefrandt JD, Wolffenbuttel BHR, Oosterwijk JC, 
Slart RHJA, Westrik IG, de Bock GH, Mourits MJE. Elevated bone turnover markers 
after risk- reducing salpingo- oophorectomy in women at increased risk for breast and 
ovarian cancer. PLoS One 2017;12:e0169673.
 11 Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in 
premenopausal women and long- term health. Menopause Int 2008;14:111–6.
 12 Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade 
M, Melton LJ. Increased risk of cognitive impairment or dementia in women who 
underwent oophorectomy before menopause. Neurology 2007;69:1074–83.
 13 Gaba F, Manchanda R. Systematic review of acceptability, cardiovascular, neurological, 
bone health and HRT outcomes following risk reducing surgery in BRCA carriers. Best 
Pract Res Clin Obstet Gynaecol 2020;65:46–65.
 14 Gan C, Chenoy R, Chandrasekaran D, Brockbank E, Hollingworth A, Vimplis S, 
Lawrence AC, Jeyarajah AR, Oram D, Deo N, Saravanamuthu J, Lam SS, Faruqi A, 
Singh N, Manchanda R. Persistence of fimbrial tissue on the ovarian surface after 
salpingectomy. Am J Obstet Gynecol 2017;217:425.e1–16.
 15 Howitt BE, Hanamornroongruang S, Lin DI, Conner JE, Schulte S, Horowitz N, Crum 
CP, Meserve EE. Evidence for a dualistic model of high- grade serous carcinoma: BRCA 
mutation status, histology, and tubal intraepithelial carcinoma. Am J Surg Pathol 
2015;39:287–93.
 16 Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, 
Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of ovarian cancer 
progression reveals diverse metastatic trajectories including intraepithelial metastasis 
to the fallopian tube. Cancer Discov 2016;6:1342–51.
 17 Gaba F, Piek J, Menon U, Manchanda R. Risk- reducing early salpingectomy and 
delayed oophorectomy as a two- staged alternative for primary prevention of ovarian 
cancer in women at increased risk: a commentary. BJOG 2019;126:831–9.
 18 Arts- de Jong M, Harmsen MG, Hoogerbrugge N, Massuger LF, Hermens RP, de Hullu 
JA. Risk- reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation 
carriers: patients’ and professionals’ perspectives. Gynecol Oncol 2015;136:305–10.
 19 Gaba F, Blyuss O, Chandrasekaran D, Osman M, Goyal S, Gan C, Izatt L, Tripathi 
V, Esteban I, McNicol L, Ragupathy K, Crawford R, Evans DG, Legood R, Menon 
U, Manchanda R. Attitudes towards risk- reducing early salpingectomy with 
delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG 2020. 
doi:10.1111/1471-0528.16424. [Epub ahead of print: 16 Aug 2020].
 20 Hallowell N. A qualitative study of the information needs of high- risk women 
undergoing prophylactic oophorectomy. Psychooncology 2000;9:486–95.
 21 Hallowell N, Jacobs I, Richards M, Mackay J, Gore M. Surveillance or surgery? A 
description of the factors that influence high risk premenopausal women’s decisions 
about prophylactic oophorectomy. J Med Genet 2001;38:683–91.
 22 Babb SA, Swisher EM, Heller HN, Whelan AJ, Mutch DG, Herzog TJ, Rader JS. 
Qualitative evaluation of medical information processing needs of 60 women 
choosing ovarian cancer surveillance or prophylactic oophorectomy. J Genet Couns 
2002;11:81–96.
 on M








enet: first published as 10.1136/jm





11Gaba F, et al. J Med Genet 2021;0:1–11. doi:10.1136/jmedgenet-2020-107501
Cancer genetics
 23 Makoul G, Clayman ML. An integrative model of shared decision making in medical 
encounters. Patient Educ Couns 2006;60:301–12.
 24 Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic 
findings of prophylactic salpingo- oophorectomies in 159 BRCA1 and BRCA2 carriers. 
Gynecol Oncol 2006;100:58–64.
 25 Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic 
salpingectomy with delayed oophorectomy as risk- reducing surgery among BRCA 
mutation carriers. Gynecol Oncol 2014;133:283–6.
 26 Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG. Risk of 
contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30- year semi- 
prospective analysis. Fam Cancer 2015;14:531–8.
 27 Heemskerk- Gerritsen BAM, Seynaeve C, van Asperen CJ, Ausems MGEM, Collée JM, 
van Doorn HC, Gomez Garcia EB, Kets CM, van Leeuwen FE, Meijers- Heijboer HEJ, 
Mourits MJE, van Os TAM, Vasen HFA, Verhoef S, Rookus MA, Hooning MJ, Hereditary 
Breast and Ovarian Cancer Research Group Netherlands. Breast cancer risk after 
salpingo- oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence 
for risk reduction. J Natl Cancer Inst 2015;107:djv033.
 28 Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan 
B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng 
C, Pal T, Evans G, Sun P, Lubinski J, Narod SA, The Hereditary Breast Cancer Clinical 
Study Group. Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 
Mutation Carriers. J Natl Cancer Inst 2017;109.
 29 Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, Singer CF, Fruscio R, 
Couch F, Weitzel JN, Karlan B, Foulkes WD, Moller P, Eisen A, Ainsworth P, Neuhausen 
SL, Olopade O, Sun P, Gronwald J, Narod SA, Hereditary Breast Cancer Clinical Study 
Group. Oophorectomy and risk of contralateral breast cancer among BRCA1 and 
BRCA2 mutation carriers. Breast Cancer Res Treat 2019;175:443–9.
 30 Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger 
LF, Gaarenstroom KN, Mourits MJE, Verheijen RHM, van Dorst EBL, van der Putten H, 
van der Velden K, Boonstra H, Aaronson NK. Quality- Of- Life effects of prophylactic 
salpingo- oophorectomy versus gynecologic screening among women at increased risk 
of hereditary ovarian cancer. J Clin Oncol 2005;23:6890–8.
 31 Madalinska JB, van Beurden M, Bleiker EMA, Valdimarsdottir HB, Hollenstein J, 
Massuger LF, Gaarenstroom KN, Mourits MJE, Verheijen RHM, van Dorst EBL, van 
der Putten H, van der Velden K, Boonstra H, Aaronson NK. The impact of hormone 
replacement therapy on menopausal symptoms in younger high- risk women after 
prophylactic salpingo- oophorectomy. J Clin Oncol 2006;24:3576–82.
 32 Harmsen MG, Arts- de Jong M, Hoogerbrugge N, Maas AHEM, Prins JB, Bulten J, 
Teerenstra S, Adang EMM, Piek JMJ, van Doorn HC, van Beurden M, Mourits MJE, 
Zweemer RP, Gaarenstroom KN, Slangen BFM, Vos MC, van Lonkhuijzen LRCW, 
Massuger LFAG, Hermens RPMG, de Hullu JA, salpingectomy E. Early salpingectomy 
(TUbectomy) with delayed oophorectomy to improve quality of life as alternative for 
risk- reducing salpingo- oophorectomy in BRCA1/2 mutation carriers (tuba study): a 
prospective non- randomised multicentre study. BMC Cancer 2015;15:593.
 33 Manchanda R, Burnell M, Abdelraheim A, Johnson M, Sharma A, Benjamin E, Brunell 
C, Saridogan E, Gessler S, Oram D, Side L, Rosenthal AN, Jacobs I, Menon U. Factors 
influencing uptake and timing of risk reducing salpingo- oophorectomy in women 
at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG 
2012;119:527–36.
 34 Braude L, Kirsten L, Gilchrist J, Juraskova I. A systematic review of women’s 
satisfaction and regret following risk- reducing mastectomy. Patient Educ Couns 
2017;100:2182–9.
 35 Brown SL, Whiting D, Fielden HG, Saini P, Beesley H, Holcombe C, Holcombe S, 
Greenhalgh L, Fairburn L, Salmon P. Qualitative analysis of how patients decide that 
they want risk- reducing mastectomy, and the implications for surgeons in responding 
to emotionally- motivated patient requests. PLoS One 2017;12:e0178392.
 36 Howard AF, Bottorff JL, Balneaves LG, Kim- Sing C. Women’s constructions of the 
’right time’ to consider decisions about risk- reducing mastectomy and risk- reducing 
oophorectomy. BMC Womens Health 2010;10:24.
 37 Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, 
Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, 
Hamilton CA, Bakkum- Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang 
HQ, Wenzel L. Factors associated with deciding between risk- reducing salpingo- 
oophorectomy and ovarian cancer screening among high- risk women enrolled in 
GOG-0199: an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 
2017;145:122–9.
 38 NICE, Familial breast cancer. Classification and care of people at risk of familial breast 
cancer and management of breast cancer and related risks in people with a family 
history of breast cancer. In: Nice clinical guideline CG164. London, UK: National 
Institute for Health and Care Excellence, 2013.
 39 Myklebust M, Gjengedal E, Strømsvik N. Experience of Norwegian female BRCA1 and 
BRCA2 Mutation- Carrying participants in educational support groups: a qualitative 
study. J Genet Couns 2016;25:1198–206.
 40 Khadim MF, Eastwood P, Price J, Morrison P, Khan K. Multidisciplinary one- stage 
risk- reducing gynaecological and breast surgery with immediate reconstruction in 
BRCA- gene carrier women. Eur J Surg Oncol 2013;39:1346–50.
 41 Hunsinger V, Marchac AC, Derder M, Hivelin M, Lecuru F, Bats A- S, Lantieri L. A 
new strategy for prophylactic surgery in BRCA women: combined mastectomy and 
laparoscopic salpingo- oophorectomy with immediate reconstruction by double DIEP 
flap. Ann Chir Plast Esthet 2016;61:177–82.
 42 Huber J, Muck T, Maatz P, Keck B, Enders P, Maatouk I, Ihrig A. Face- To- Face vs. online 
peer support groups for prostate cancer: a cross- sectional comparison study. J Cancer 
Surviv 2018;12:1–9.
 43 Gold KJ, Normandin MM, Boggs ME. Are participants in face- to- face and Internet 
support groups the same? comparison of demographics and depression levels among 
women bereaved by stillbirth. Arch Womens Ment Health 2016;19:1073–8.
 44 Hu A. Reflections: the value of patient support groups. Otolaryngol Head Neck Surg 
2017;156:587–8.
 45 McCaughan E, Parahoo K, Hueter I, Northouse L, Bradbury I. Online support groups 
for women with breast cancer. Cochrane Database Syst Rev 2017;3.
 46 Antoniou AC, Pharoah PPD, Smith P, Easton DF. The BOADICEA model of genetic 
susceptibility to breast and ovarian cancer. Br J Cancer 2004;91:1580–90.
 on M








enet: first published as 10.1136/jm
edgenet-2020-107501 on 10 F
ebruary 2021. D
ow
nloaded from
 
